Hot Topic — GLP-1 & Aesthetics

GLP-1, Ozempic Face
& The Role of Mesotherapy

GLP-1 receptor agonists (Ozempic, Wegovy, Mounjaro) have transformed weight management — but they have also created a new aesthetic challenge that is arriving in clinics daily. Every aesthetic practitioner needs to understand what happens to the face after rapid weight loss, and what mesotherapy can do about it.

Visit somuk.co.uk →

SoMUK · Founded 2013 · 22 Harley Street, London · Accredited Training · somuk.co.uk

“I am seeing more patients than ever who come in looking older than they did a year ago — and they cannot understand why. They have lost weight, they feel better, they expected to look better. Instead their face looks hollow, deflated, and aged. GLP-1 medications are extraordinarily effective. But the aesthetic consequences of rapid facial fat loss are real, significant, and require a structured clinical response. Mesotherapy is part of that response.” — Dr Philippe Hamida-Pisal, Medical Advisor, SoMUK

What is Ozempic face?

Understanding the aesthetic consequences of GLP-1 medications

GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro), liraglutide (Saxenda) — work by mimicking the glucagon-like peptide-1 hormone to reduce appetite and slow gastric emptying. Their weight loss results can be dramatic: 15–25% total body weight reduction in clinical trials. But rapid, significant weight loss does not discriminate between body fat and facial fat.

“Ozempic face” is the colloquial term for the constellation of aesthetic changes that occur in the face following rapid weight loss on GLP-1 medications. It is not caused by the drug itself — it is caused by rapid fat loss from facial compartments that normally provide volume, structure, and support to the overlying skin.

How common is it?

A 2025 survey of 1,200 aesthetic practitioners in the UK and US found that 68% reported a significant increase in patients seeking facial rejuvenation following GLP-1 weight loss . The aesthetic consequences are most pronounced in patients who lose more than 10% of body weight rapidly — typically within 3–6 months of starting medication.

The clinical picture

What Ozempic face actually looks like — four phases

Phase 01

Facial fat compartment volume loss

The buccal fat pad, malar fat pad, and deep medial cheek fat deflate. The face appears hollowed in the mid-face, temples, and periorbital region. Cheekbones become more prominent but in a gaunt rather than structured way. The overall impression is of a face that appears significantly older than it did before weight loss.

Phase 02

Skin laxity and sagging

The skin that previously had fat volume beneath it now has less structural support. Jowling becomes more apparent. The nasolabial folds deepen. The neck and jawline lose definition. In patients over 45, pre-existing skin laxity becomes dramatically more visible as the fat that was masking it disappears.

Phase 03

Skin quality deterioration

Rapid weight loss is associated with reduced collagen synthesis, skin thinning, and dehydration. The skin often appears more crepey, less luminous, and more aged in texture. This is compounded by the nutritional changes that often accompany caloric restriction on GLP-1 medications.

Phase 04

Muscle and structural changes

GLP-1 medications in some patients are associated with loss of lean muscle mass alongside fat loss. In the face, this can reduce the structural support provided by the underlying musculature, contributing to further apparent laxity and ageing.

Where mesotherapy fits

The role of mesotherapy in the GLP-1 aesthetic response

Mesotherapy cannot restore fat volume — that requires dermal fillers or biostimulators. But it plays a critical and often underappreciated role in addressing the skin quality and structural changes that accompany facial fat loss. In the context of Ozempic face, mesotherapy addresses three specific mechanisms:

Mechanism	How mesotherapy helps
Skin quality restoration	Vitamin and amino acid-rich cocktails restore the nutritional environment of the dermis — reversing the skin thinning, dehydration, and crepiness associated with rapid weight loss. Hyaluronic acid components restore deep dermal hydration.
Collagen stimulation	Growth factor delivery, vitamin C, and peptide cocktails stimulate fibroblast activity and collagen synthesis — improving skin thickness and elasticity that was lost during rapid weight loss.
Tissue preparation for other treatments	Mesotherapy applied 2–3 weeks before filler or biostimulator treatment primes the tissue, improves integration, and enhances the longevity of subsequent volumising treatments.
Reducing skin laxity progression	Polynucleotides combined with mesotherapy stimulate structural tissue repair, reducing the rate at which skin laxity progresses in the months following rapid weight loss.
Supporting nutritional deficiencies	Patients on GLP-1 medications often eat significantly less and may have nutritional deficiencies (B vitamins, zinc, amino acids) that directly impact skin health. Intradermal delivery bypasses the reduced dietary intake.

The SoMUK Clinical Position

“Mesotherapy is not the primary treatment for Ozempic face — volume restoration with fillers or biostimulators is the foundation. But mesotherapy should be the first treatment in the sequence, and the ongoing maintenance treatment throughout the weight loss journey. It is the tool that preserves skin quality while everything else is changing.”

The protocol

Recommended clinical approach for GLP-1 patients

Stage	Protocol
During active weight loss	Mesotherapy first: begin nutritional and hydration mesotherapy cocktails from the start of significant weight loss. Monthly sessions. Focus on vitamin B complex, amino acids, HA, growth factors. Do NOT volumise during active weight loss — the face is still changing and filler placed now may look wrong in 3 months.
Weight stabilisation (3+ months stable)	Assessment and plan: once weight is stable for at least 3 months, assess residual volume loss, laxity, and skin quality. Begin combined protocol: mesotherapy for skin quality + biostimulator (Sculptra, Radiesse) or polynucleotides for structural support.
Volume restoration phase	Fillers and biostimulators: 2–3 weeks after mesotherapy priming, introduce targeted filler for specific volume deficits (malar, temple, jawline). Biostimulators for diffuse volume and structural support. Continue mesotherapy in alternating sessions.
Maintenance	Ongoing mesotherapy every 6–8 weeks to sustain skin quality. Reassess volume every 6–12 months. Many GLP-1 patients remain on medication long-term — skin quality maintenance is ongoing.

Important Clinical Warning

Do not volumise a face that is still losing weight. Filler placed during active GLP-1 weight loss will shift, migrate, and look abnormal as the surrounding fat continues to deflate. The most common complaint from patients who had filler during GLP-1 weight loss is that the filler now looks wrong. Wait for weight stabilisation — mesotherapy is the appropriate intervention during the active loss phase.

Patient FAQs

What patients ask about GLP-1 and their face

I am on Ozempic and my face looks older. What should I do first?

The first step is a consultation to assess what has changed: is it primarily volume loss, skin quality, laxity, or a combination? If you are still actively losing weight, the right immediate intervention is mesotherapy to preserve skin quality — not fillers. Once your weight has been stable for at least 3 months, a structured volumisation and skin quality programme can be designed.

Can I have fillers while I am still on Ozempic?

We strongly advise against it during active weight loss. The facial fat continues to shift as weight decreases, meaning filler placed now may look incorrect within weeks. The exception is very targeted correction of a specific deficit that has been stable — but this requires careful clinical judgement. Begin with mesotherapy and reassess when stable.

Will stopping the medication reverse Ozempic face?

Most patients regain weight when GLP-1 medication is stopped, and some facial volume may return. However, the skin quality deterioration — laxity, thinning, loss of elasticity — does not automatically reverse with weight regain. Proactive skin quality treatment during the weight loss phase significantly reduces the severity of this issue.

How many mesotherapy sessions will I need?

During active weight loss: monthly sessions at minimum. Once stable: 4–6 sessions over 8–12 weeks as a restorative course, then maintenance every 6–8 weeks. Most GLP-1 patients who start mesotherapy early see significantly better skin quality outcomes than those who wait until weight loss is complete.

Upcoming Training

2026 Masterclass Dates

22 Harley Street, London · Max 4 delegates · £600 per delegate · CPD accredited

Date	Course	Spaces	Book
Sat 4 Jul	Aesthetic Aesthetic Mesotherapy	4 left	BOOK
Sun 5 Jul	Exosomes Skin Boosters Exosomes & Skin Boosters	4 left	BOOK
Sun 12 Jul	Pain Pain Management	4 left	BOOK
Sat 22 Aug	Aesthetic Aesthetic Mesotherapy	4 left	BOOK
Sun 23 Aug	Aesthetic Exosomes Mesotherapy & Exosomes	4 left	BOOK

View all 22 dates at somuk.co.uk/training-calendar/

Society of Mesotherapy UK

Train to treat GLP-1 patients at SoMUK

Aesthetic mesotherapy training at 22 Harley Street, London. GLP-1 aesthetic management covered in advanced modules.

View Training Dates → Become a Member

contact@somuk.co.uk · +44 20 7580 9095 · 22 Harley Street, London W1G 9PL

GLP-1, Ozempic Face & The Role of Mesotherapy